David W Haas MD
Professor, Medicine, Vanderbilt University School of Medicine
Join to view full profile
3601 21st Ave SNashville, TN 37232
Phone+1 615-322-3000
Fax+1 615-936-0605
Dr. Haas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Infectious Disease, 1987 - 1988- Vanderbilt University Medical CenterResidency, Internal Medicine, 1983 - 1987
Vanderbilt University School of MedicineClass of 1983
Certifications & Licensure
TN State Medical License 1985 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2014
Clinical Trials
- A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body
- Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
- Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery Start of enrollment: 2014 Jul 02
Publications & Presentations
PubMed
- Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil.Jacqueline A Piekos, Gustavo Amorim, Felipe Ridolfi, Marcelo Cordeiro-Santos, Afrânio L Kritski
Human Genetics. 2026-01-06 - Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil.Felipe Ridolfi, Gustavo Amorim, David W Haas, Maria Arriaga, Cody Staats
Memorias Do Instituto Oswaldo Cruz. 2026-01-01 - 2 citationsPharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.Nia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, Rodney Dawson, Yoninah Cramer
Pharmacogenetics and Genomics. 2025-06-01
Press Mentions
Vanderbilt University Medical Center Seeks COVID-19 Patients for Participation in ACTIV-2 TrialApril 13th, 2021- Vanderbilt Seeks Volunteers for Clinical Trial to Find COVID-19 TreatmentsApril 12th, 2021
- Vanderbilt Seeks Volunteers for COVID-19 Clinical TrialApril 12th, 2021
Grant Support
- Vanderbilt HIV Clinical Trials Unit (CTU)VANDERBILT UNIVERSITY MEDICAL CENTER2007–2027
- Pharmacogenomics of HIV TherapyVANDERBILT UNIVERSITY MEDICAL CENTER2008–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
